Recently, good news came from YunKang’s Guangzhou DaAn Clinical Laboratory: in the latest round of high throughput sequencing EQAs for genetic diseases organized by the National Center for Clinical Laboratories (NCCL) and the College of American Pathologists (CAP) in 2025, the laboratory achieved perfect scores in all 7 projects, passing the dual authoritative assessments at home and abroad with solid strength. This marks that its technical capabilities and service quality in the field of genetic disease diagnosis have reached internationally advanced levels.

The 7 projects that passed with perfect scores cover key areas of genetic disease testing, including HighThroughput Sequencing of Genetic Variants, Bioinformatics Analysis of High Throughput Sequencing for Genetic Diseases, Chromosomal Genomic Structural Abnormalities, Newborn Hearing Loss Genetic Testing, DMD Gene Testing, Thalassemia Genotyping, and the CAP/ACMG Cardiomyopathy Sequencing Panel (CMSP) , totaling 7 projects.

From basic genetic variant screening to complex bioinformatics interpretation, from common genetic disease diagnosis to precise rare disease testing, YunKang has built a full chain, high standard medical testing system, achieving comprehensive certification of multi scenario testing capabilities.

As the "gold standard" for clinical laboratory quality management in China, NCCL EQA is known for its rigorous evaluation and strict criteria, serving as a core benchmark for assessing the technical strength of domestic laboratories.

CAP, the world’s largest non profit pathologist organization, established its accreditation system in the 1960s. Through a combination of standardized checklists and onsite inspections, it continuously drives quality improvement in laboratories globally. YunKang’s perfect scores in both authoritative assessments fully confirm the accuracy, reliability, and international compatibility of its testing results.

High throughput sequencing (NGS) technology, as the core support for precise diagnosis of genetic diseases, leverages its advantages of high throughput, high sensitivity, and low cost to become a key tool for identifying causative genes, guiding treatment strategies, and providing genetic counseling. YunKang’s Precision Medicine Laboratory, relying on a mature NGS platform, has deeply pursued technological innovation and process optimization. Achieving perfect scores in all projects is the best evidence of its technical professionalism and service standardization.

In particular, during the CMSP assessment, facing multiple core cardiomyopathy related genes, YunKang’s submitted test results were fully consistent with expected responses, earning a "Good" rating for all, demonstrating its internationally aligned capability for precise testing of cardiovascular genetic diseases.

This dualauthority perfect score certification not only affirms YunKang Laboratory’s technical accumulation and quality management system but also reflects the laboratory’s long standing implementation of lean operation principles – through full process standardized control, refined quality traceability, and continuous optimization of operational efficiency, ensuring that every test report withstands authoritative scrutiny.

In the future, YunKang will continue to focus on "Lean Operations · InDepth Service", deepening its commitment to the field of precision diagnosis and empowering clinical practice with more accurate technology and better service.